Pfizer breast cancer drug receives preliminary approval

April 16, 2015 6:57 AM

24 0

Pfizer Inc has halted its late stage 3 trials (PALOMA-3 trial) of ibrance breast cancer drug in combination with fulvestrant after being fortunate to get everything back on track.

The company announced to stop the study on Wednesday following an assessment of it done by an independent data monitoring committee.

Read more

To category page